Growth Metrics

Ionis Pharmaceuticals (IONS) Operating Margin (2016 - 2025)

Historic Operating Margin for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to 102.21%.

  • Ionis Pharmaceuticals' Operating Margin rose 88800.0% to 102.21% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.07%, marking a year-over-year increase of 110500.0%. This contributed to the annual value of 67.37% for FY2024, which is 224600.0% down from last year.
  • Ionis Pharmaceuticals' Operating Margin amounted to 102.21% in Q3 2025, which was up 88800.0% from 50.29% recorded in Q2 2025.
  • Ionis Pharmaceuticals' Operating Margin's 5-year high stood at 50.29% during Q2 2025, with a 5-year trough of 136.95% in Q4 2022.
  • For the 5-year period, Ionis Pharmaceuticals' Operating Margin averaged around 60.41%, with its median value being 63.92% (2022).
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Operating Margin skyrocketed by 3400800bps in 2021, and later crashed by -1870900bps in 2022.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Operating Margin stood at 50.14% in 2021, then tumbled by -373bps to 136.95% in 2022, then surged by 99bps to 1.89% in 2023, then plummeted by -2493bps to 48.91% in 2024, then crashed by -109bps to 102.21% in 2025.
  • Its Operating Margin was 102.21% in Q3 2025, compared to 50.29% in Q2 2025 and 111.59% in Q1 2025.